Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in epilepsy treatment trading at $10.67 per share, announced today that it anticipates minimal impact from tariffs on its operations and financial results for fiscal year 2025. Despite experiencing a significant 15% decline over the past week, according to InvestingPro data, the company, which manufactures the majority of its devices within the United States, has limited its supply chain activities outside the U.S. for its RNS System, a treatment for epilepsy.
The company also expects no material effect on the gross margin for DIXI Medical SEEG products, which are used for stereoelectroencephalography, a diagnostic procedure for epilepsy. With an impressive gross profit margin of 74% in the last twelve months and revenue growth of 22%, this outlook supports the company’s reiterated gross margin guidance for the year. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 5.37, though it currently appears overvalued based on Fair Value calculations.
NeuroPace previously disclosed the termination of its SEEG distribution agreement with DIXI Medical, effective October 1, 2025, with a six-month wind-down period extending into the first quarter of 2026. Despite this change, the company anticipates maintaining its financial performance.
In addition, NeuroPace will report its first quarter financial results for 2025 on May 13, 2025, after the market closes. With four analysts recently revising earnings estimates upward for the upcoming period, investors are closely watching this announcement. A conference call hosted by the company’s management is scheduled to follow the release of the financial results, providing further insights into the company’s performance and outlook. For deeper analysis and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
The company’s RNS System is touted as the first and only brain-responsive platform available commercially for the treatment of seizures at their source. With a market capitalization of $350 million and projected revenue growth of 18% for fiscal year 2025, NeuroPace aims to establish the RNS System as the standard of care for patients with drug-resistant epilepsy, potentially expanding its application to other brain disorders.
Investors and interested parties can access the conference call via a live and archived webcast, or by dialing in with the provided details. The archived webcast will be available for replay on the company’s investor relations website for at least 90 days following the event.
This announcement is based on a press release statement from NeuroPace, Inc. and does not constitute an endorsement of the company’s claims. The forward-looking statements included in the press release are subject to various risks and uncertainties, and actual results may differ materially.
In other recent news, NeuroPace Inc. shared significant findings from a three-year study of its RNS System, revealing an 82% median seizure reduction in adults with drug-resistant focal epilepsy. This study, part of the largest FDA-reviewed trial in neuromodulation for this condition, also showed that 42% of patients achieved seizure freedom for at least six consecutive months. NeuroPace announced the termination of its distribution agreement for Stereo EEG products by the fourth quarter of 2025 to focus on its core RNS System, maintaining its 2025 revenue guidance and expecting cash flow breakeven by the end of 2027. Cantor Fitzgerald recently adjusted its price target for NeuroPace from $20 to $17 while maintaining an Overweight rating, following the presentation of positive data from the company’s Long-Term Post-Approval Study at the American Academy of Neurology Annual Meeting. The firm’s analysis suggests confidence in the growth trajectory of NeuroPace, emphasizing the potential for increased adoption of the RNS System. Project CARE, an initiative aimed at expanding the reach of the RNS System, is expected to drive further growth. NeuroPace’s strategic moves, including potential indication expansion and AI-enabled software launches, align with its long-term growth plans centered around the RNS System. These developments highlight the company’s ongoing efforts to enhance its market position and expand its innovative treatment options for epilepsy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.